Article
PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
Lung cancer (Amsterdam, Netherlands) - 1 Jan 2011
Pu Xia, Hildebrandt Michelle A T, Lu Charles, Lin Jie, Stewart David J, Ye Yuanqing, Gu Jian, Spitz Margaret R, Wu Xifeng
Abstract excerpt
Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related deaths. The effect of the PI3K/PTEN/AKT/mTOR signaling pathway on cancer treatment, including NSCLC, has been well documented. In this study, we analyzed associations between genetic variations within this pathway and clinical outcomes following platinum-based chemotherapy in 168 patients with stage IIIB (wet) or stage IV NSCLC....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
